01-PJ4-PG4-01VN PDF

Similar documents
( )박용주97.PDF

334 退 溪 學 과 儒 敎 文 化 第 55 號 角 說 에서는 뿔이 난 말과 고양이라는 기형의 동물을 소재로 하여 당대 정치 상 황을 비판하였고, 白 黑 難 에서는 선과 악을 상징하는 색깔인 白 과 黑 이 서로 벌이 는 문답을 통하여 옳고 그름의 가치관이 전도된 현실세

정봉수.PDF

논문수정본.PDF

a16.PDF

Pharmacotherapeutics Application of New Pathogenesis on the Drug Treatment of Diabetes Young Seol Kim, M.D. Department of Endocrinology Kyung Hee Univ

歯논문손규만.PDF

PDF

歯FFF01379.PDF

歯D13236_F1.PDF

012임수진

겉표지.PDF

歯320.PDF

PDF

Lumbar spine

이수진.PDF

歯 PDF

PBR PDF

°ø±â¾Ð±â±â

May 10~ Hotel Inter-Burgo Exco, Daegu Plenary lectures From metabolic syndrome to diabetes Meta-inflammation responsible for the progression fr

歯신용카드시장현상.PDF

16(1)-3(국문)(p.40-45).fm

A 617

hwp

µµ≈•∏‡∆Æ1

歯연보99-6.PDF

???짚?


FTA 활용 종합 가이드북 cha Pte r04 원 楓 기준,:산지증명 Im 飇 10 chapte 硼 FTA 爵 x녠저 匡 모델01 FrA 상대국관세을인하를활용한수출확대 첫번째 모델은 우리가 F fa 를 체결하는 가장 중요한 이유인 상대국의 관세을 인하를수출확대기회로활

보관본.PDF

歯 PDF

歯PLSQL10.PDF

歯95_dbtech.PDF

歯 PDF

페링야간뇨소책자-내지-16

레이아웃 1

901-(Twin)¿ë AB


Sheu HM, et al., British J Dermatol 1997; 136: Kao JS, et al., J Invest Dermatol 2003; 120:

main.hwp

13 2 ( 25 ) Korean J Med Hist Dec 2004 ISSN X * ( ) ( ) ( ). 1) ( ) ( ) ( ) ( ) ( ) 2) ( ) 3) 1990 ( ) 4) * 1) ( ) C

歯IC-706.PDF

歯프로그램.PDF

Index 정육 홍성 한우 04 육가공 제주 흑돼지 소시지 장흥 한우육포 수산물 제주 갈치ㆍ고등어ㆍ옥돔 영광 황토굴비 완도 전복 통영 참멸치 기장 미역 & 다시마 과일 나주 배 청도 반시 광양 청매실 구례 산수유 음성 블루베리 42

16_이주용_155~163.hwp

Bchvvhv[vhvvhvvhchvvhvvhvvhvvhvvgvvgvv}vvvgvvhvvhvvvhvvhvvhvvvbbhvvhvvvgvvgvvhvvhvvhv}hv,.. Bchvvhv[vhvvhvvhvvhvvbbhvvhvvhvvvhvvhvvgvvgvv}vvgvvhvvvhvv

최종욱.PDF

송동우.PDF

A C O N T E N T S A-132

歯5-2-13(전미희외).PDF

歯FFF01288.PDF

THE E-LAND Group C S R A n n u a l R e p o r t www elandcsr or kr CSR CSR A 2 TEL FAX

105È£4fš

<BBE7B6FBB9E B0A1C0BBC0DBBEF7C1DF2E696E6464>

목 차 회사현황 1. 회사개요 2. 회사연혁 3. 회사업무영역/업무현황 4. 등록면허보유현황 5. 상훈현황 6. 기술자보유현황 7. 시스템보유현황 주요기술자별 약력 1. 대표이사 2. 임원짂 조직 및 용도별 수행실적 1. 조직 2. 용도별 수행실적

완성09E02박은숙.PDF

Microsoft PowerPoint - ch03ysk2012.ppt [호환 모드]

DY1932(단면).hwp

Part.1 당뇨병 관리의 첫걸음, 당뇨병 알기 당뇨병이란? 당뇨병의 원인은 무엇일까? 당뇨병의 종류 당뇨병의 증상과 진단 당뇨병의 치료 12 Part.2 당뇨병과 식사관리 당뇨병과 올바른 식사 23 2.

<3034C0D3BBF3C3E1B0E8C7D0BCFABCBCB9CCB3AA2E687770>

초보자를 위한 C++

초보자를 위한 ASP.NET 2.0

1. 화섬산업의 개요 1.1 화섬산업의 륵성 화 섬산 업 의 산 업 적 특 성 화섬산업은 원사,원면 둥 기초소재를 생산하는 섬유산 업의 핵심산업으로 고용창출효과와 고부가가치를 실현할 수 있음 O 세계적으로 독일,이태리,일본 등 선진국을 중심으로 M E(마이크로 일렉트

ÃÖ»óÀ§5³ª-Á¤´ä(01~23)

< C7D0B3E2B5B520B4EBBCF6B4C920C7D8BCB3C1F628B1B9BEEE41C7FC20C8A6BCF6292E687770>

< FC1F8B9E6B1B3C0B02E687770>

<C3CA3520B0FAC7D0B1B3BBE7BFEB202E687770>

212.

第 1 節 組 織 11 第 1 章 檢 察 의 組 織 人 事 制 度 등 第 1 項 大 檢 察 廳 第 1 節 組 대검찰청은 대법원에 대응하여 수도인 서울에 위치 한다(검찰청법 제2조,제3조,대검찰청의 위치와 각급 검찰청의명칭및위치에관한규정 제2조). 대검찰청에 검찰총장,대

6À嵶¼º¿¬±¸ºÐ¾ß


DV690-N_KOR_ indd

1.PDF

2014_트렌드씨_웹용_1월_s

untitled

141(26) () ( ( ) () () () ) 2) 1932 ()()3) 2 1) ( ) ( ) () () () 4) ( ) 5) 6) ) ) ( ) () 42 () )

User's Guide


< D B4D9C3CAC1A120BCD2C7C1C6AEC4DCC5C3C6AEB7BBC1EEC0C720B3EBBEC8C0C720BDC3B7C2BAB8C1A4BFA120B4EBC7D120C0AFBFEBBCBA20C6F2B0A E687770>

전립선암발생률추정과관련요인분석 : The Korean Cancer Prevention Study-II (KCPS-II)

6 강남구 청담지구 청담동 46, 삼성동 52 일대 46,592-46,592 7 강남구 대치지구 대치동 922번지 일대 58,440-58,440 8 강남구 개포지구 개포동 157일대 20,070-20,070 9 강남구 개포지구중심 포이동 238 일대 25,070-25,

27집최종10.22

황룡사 복원 기본계획 Ⅵ. 사역 및 주변 정비계획 가. 사역주변 정비구상 문화유적지구 조성 1. 정비방향의 설정 황룡사 복원과 함께 주변 임해전지(안압지) 海殿址(雁鴨池)와 분황사 등의 문화유적과 네트워크로 연계되는 종합적 정비계획안을 수립한다. 주차장과 광장 등 주변

歯 PDF

2 농정 더불어민주당, 도시지역 의원 농해수위 배정 눈총 농촌지역구 의원 농해수위 꺼려 농업전문 역량 갖춘 보좌진 가뭄 전남북 정치지형 변화 농해수위까지 불똥 여소야대 국회, 야당 농민위해 적극 나서야 국회 농해수위가 눈총을 받고 있다. 총선 이후 정치지형이 변화되면서

텀블러514


A 001~A 036

KARAAUTO_1¿ù.qxd.ps, page Normalize


Microsoft Word - IO_2009_메모리반도체.doc

DBPIA-NURIMEDIA

歯2800.PDF

hwp

주지스님의 이 달의 법문 성철 큰스님 기념관 불사를 회향하면서 20여 년 전 성철 큰스님 사리탑을 건립하려고 중국 석굴답사 연구팀을 따라 중국 불교성지를 탐방하였습 니다. 대동의 운강석굴, 용문석굴, 공의석굴, 맥적산석 굴, 대족석굴, 티벳 라싸의 포탈라궁과 주변의 큰

1 1. (,, ) ( ) (,,, )., 1 ( ), ( ) ( ) 30, ( ) , + 1%., 1.

윈도우 자동실행 설정 방법.PDF

달생산이 초산모 분만시간에 미치는 영향 Ⅰ. 서 론 Ⅱ. 연구대상 및 방법 達 은 23) 의 丹 溪 에 최초로 기 재된 처방으로, 에 복용하면 한 다하여 난산의 예방과 및, 등에 널리 활용되어 왔다. 達 은 이 毒 하고 는 甘 苦 하여 氣, 氣 寬,, 結 의 효능이 있

112초등정답3-수학(01~16)ok

No Title

Transcription:

1 : ( ) (0 1- PJ4- PG4-0 1VN02-0055) ( ) : ( ) :De ve lo pme nt of the functio na l food for tre atme nt of diabe te s me llitus with a new me cha nis m of actio n : () :

1 : (, ) ( ) ( ) 1.. 2.. (14 pont, ) 6cm

2 : 01- P J4 - P G4-0 1V N 02-0055 ). 2002. 05. 25 :() : 1: (1 / 1) :()

3 :. ( ) ( )Development of the functional food for treatment of diabetes mellitus with a new mechanism of action. 1. - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 1 2. - - - - - - - - - - - - - - - - - - - - - - - - - - - - 3 3. - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 186 4. - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 187 5. - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 188 6. - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 189 7. - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 190

4 : ( ),, () () 2001420025 2 ob/ ob m ou se db/ db m ou se INM 803glu cose in sulin toleran ce,. leptin m ou seob/ ob m ou se db/ db m ou seinm80380% eth anol ex tract 9 0.05%, 0.1%, 0.2%on e- w ay ANOVA test. ob/ ob m ou se INM 803 0.05% 0.1% 0.2%6 (P < 0.05). 6(P < 0.05) 0.2%. plasm a in sulin 3(p< 0.05). db/ db m ou se INM 803 0.05% 0.1% 0.2%,. in sulin toleran ce testglucose tolerance test. INM 803 3690.1% 0.2%.(p < 0.05) INM 803 INM 803 2000 m g/ kg14.. INM 803 2000 m g/ kg. INM 803.

5 : ( ) Project S ummery,, 2. Development of the functional food for treatment of diabetes mellitus with a new T it le mechanism of action K ey W ords treatment of diabetes mellitus, functional food, a new mechanism of action In s tit ut e Biosyn ergen Inc. P roj e ct L e ader Don g - keun,song A s s o ci at e d Com pan y P roj e ct P eri od 2001. 4. 2002. 5. Biosynerg en In c. T o dev elop an effectiv e and safe food/ dru g for reducing high blood su gar, w e studied th e effect of INM - 803 in blood sug ar redu cin g effect, in sulin tolerance, an d acute tox icity u sing type 2 diab etes anim al m odels, ob/ ob m ou se and db/ db mou se. INM - 803 (80% eth anol ex tract ; 0.05%, 0.1%, 0.2% ) w as administered orally for 9 w eek s to ob/ ob m ou se, w hich lack s leptin. INM 803 (0.05% 0.1% 0.2% ) decr eased blood su gar lev els fr om 6 w eek of administration in ob/ ob m ou se. Plasm a in sulin lev els sh ow ed a significant decrease (p< 0.05) fr om 6 w eek of adm inistr ation. INM 803 (0.05% 0.1% 0.2% ) also decreased blood su gar lev els in db/ db m ou se w ith out chan ges in body w eight. Interestingly, the INM803- induced decrease in blood su gar lev els w a s maintained up to 9 w eek s after discontinuation of INM - 803 (p< 0.05). T o study th e acute toxicity of INM - 803, INM - 803 w as administered in a sin gle oral dose of 2000 m g/ kg. And anim als w ere ob serv ed for toxic symptom s for 14 day s in m ale an d female rats. N o tox ic clinical m anifestation s w ere ob serv ed inclu ding lethality. No path ological findin g s w ere ob serv ed in autopsy. T he lethal dose of INM - 803 is con sidered to be ab ov e 2000 m g/ kg. In conclu sion, it is su gg est ed that ILM - 803 can be a v ery effectiv e in corr ection of high blood su gar w ith a good safety pr ofile.

6 : 1. 1. 20 1, 15, 105. 2030 3 (Harris, 1998). 1 2-4, (blindness)., 400., 8%- 10%.,.. 90%- 95% 2. 2 db/ db mouse INM803 INM803 INM803, NM803 9, INM803.,,. INM803,. INM803,,. INM803 (BS219), INM803 BS219.

INM803. INM803 INM803BS219 INM803 BS219 INM803 BS219 INM803,. 1. INM8032db/ db ob/ ob, 1streptozotocin.. 2. INM803 BS2192db/ db ob/ ob, 1streptozotocin.. 3. INM803glu cose toleran ce test in sulin tolerance test,, cdna array. glucose tran sporterglut 4, IRS 1-4 (in sulin receptor sub strate) (immun ohistochemistry ). 4. INM803 BS219glu cose toleran ce test in sulin tolerance test,, cdna array. glu cose tran sporter GLUT 4, IRS 1-4 (in sulin receptor sub strate ) (immun ohistochemistry ) (in situ hybridization, RT - PCR, N orthern blot, w estern blot ). 5. INM803 BS219( ), ( ) 4, (3 ) 6. INM80390%-,. (10 kg). ( 1 )

7. BS219BS 219 chir al sy nth ondiol. (2 ) 2. 1) INM8032ob/ ob INM803 (0.05%, 0.1%, 0.2% ) INM803,, (1) ob/ ob 8(0 time) 230 mg/ dl17(9). INM803INM803 (0.05%, 0.1%, 0.2% ) INM80360.05% (p < 0.001), 0.1% (p < 0.001), 0.2% (p < 0.001)(Fig 1 ) (2) ob/ ob 8(0 time) 25 g17(9) 46g. INM803INM803 0.2% (p< 0.05) (F ig 2 ) (3) ob/ ob 8(0 time) 5 ng/ dl mouse 10 17(9). INM803 INM803 (0.05%, 0.1%, 0.2% )INM803 30.2% (p< 0.05) 9INM803 (0.05%, 0.1%, 0.2% ) (F ig3 ) 2 ) INM8032db/ db INM803 (0.05%, 0.1%, 0.2% ),,, (1) db/ db 8(0 time) 100 mg/ dl 17(9) 500 mg/ dl. INM803 INM803 (0.05%, 0.1%, 0.2% )INM803 90.05% (p < 0.05), 0.1% (p< 0.01), 0.2% (p< 0.01) (F ig4 ) (2) db/ db 8(0 time) 30 g17(9)

(3) ob/ ob 8(0 time) 10 ng/ dl mouse 10 7ng/ 17(9). INM803INM803 (0.05%, 0.1%, 0.2% ) INM803.(Fig 6) (4) INM803glucose 2db/ db INM803 (0.05%, 0.1%, 0.2% )9 db/ db m ou se 12glu cose (2g/ kg ) 30. (Fig 7) (5) INM803 2db/ db INM803 (0.05%, 0.1%, 0.2% )9 db/ db m ou se 12in sulin (0.5 unit/ kg ) 30 INM803 0.1% (p < 0.01), 0.2% (p< 0.05). (Fig 8) 3 ) INM803 2db/ db INM803 (0.05%, 0.1%, 0.2% )9 INM 803 9, 9INM803 0.05% (p< 0.01), 0.1% (p < 0.01), 0.2% (p < 0.001) (Fig 9) 4 ) 1 streptozotocin streptozotocin (250 m g/ kg ) 1 300 m g/ dl mou se INM803 (0.05%, 0.1%, 0.2% )9 (Fig 10) 5) BS2192db/ db INM803 (0.002%, 0.01%, 0.03% ), (1) db/ db 8(0 time) 200 mg/ dl 17(9). INM803BS219 (0.05%, 0.1%, 0.2% ) INM803(F ig 11) (2) INM803BS219 (0.05%, 0.1%, 0.2% )INM803 (Fig 12) 6) INM803 2,000mg/ kg 14. (1)

7) 2 INM 803 1,600mg/ kg 1,600mg 800 mg/ kg. (2 ) 8) Chinese Hamster Lung (CHL) INM 803 CHL. ( 3 )

Fig. 1. ob/ ob mouse INM 803. ob/ ob mouseinm 8030, 0.05 %, 0.1 %, 0.2 % 3. * P<0.05, *** P<0.001 (n=6)

Fig. 2. ob/ ob mouse INM 803. ob/ ob mouseinm 8030, 0.05 %, 0.1 %, 0.2 % 3. * P<0.05 (n=6)

Fig. 3. ob/ ob mouse INM 803. ob/ ob mouseinm 8030, 0.05 %, 0.1 %, 0.2 % 3 enzyme- immunoassay. * P<0.05, ** P< 0.01 (n=6)

Fig. 4. db/ db mouse INM 803. db/ db mouseinm 8030, 0.05 %, 0.1 %, 0.2 % 3. * P<0.05, ** P<0.01 (n =6)

Fig. 5. db/ db mouse INM 803. db/ db mouseinm 8030, 0.05 %, 0.1 %, 0.2 % 3.

Fig. 6. db/ db mouse INM 803. db/ db mouseinm 8030, 0.05 %, 0.1 %, 0.2 % 3 enzyme- immunoassay.

Fig. 7. INM803glucose 2db/ db INM803 (0.05%, 0.1%, 0.2% )9 db/ db mou se 12 glucose (2g/ k g ) 30. (n =6)

Fig. 8. INM803 2db/ db INM803 (0.05%, 0.1%, 0.2% )9 db/ db mou se 12 in sulin (0.5 unit/ kg ) 30. * P<0.05, ** P<0.01 (n =6)

Fig. 9. INM803 2db/ db INM803 (0.05%, 0.1%, 0.2% )9 INM 803 3. ** P<0.01, *** P<0.001 (n =6)

Fig. 10. 1streptozotocin streptozotocin 250 m g/ k g 1 300 m g/ dl m ou se INM803 0.05%, 0.1%, 0.2%9.

Fig. 11. db/ db mouse INM 219. db/ db mouseinm 2190, 0.002 %, 0.01 %, 0.03 % 3.

Fig. 12. db/ db mouse INM 219. db/ db mouseinm 2190, 0.002 %, 0.01 %, 0.03 % 3.

3.. 5% 90% 2( ) 1,600 14. 2 db/ db mouse INM803. INM803, NM803 9. INM803.,. INM803 INM803 2,000mg/ kg 14,. 2 INM 803 1,600mg/ kg 1,600mg 800 mg/ kg, Chinese Hamster Lung (CHL) INM 803CHL. INM803.

4. 1 (: ) 3 2 (: ) 3 (: ) 4 (: ) 3 (1) SCI (Impact Factor ) SCI (2) (3 ) (4 ) 1)(),,, 2002-1508, 2002. 01. 10. 2)(),,, 40-2001- 0027457, 2001.06.25 3)(), Glu care,, 40-2001- 0030939, 2001.07.13 (5 )

(6 ).. INM803 db/ db mou se, ob/ ob m ou se, streptozotocin m ou se 60.1% INM803 glucose tolerance test in sulin toleran ce test glucose in sulin. B S219 BS 219. INM803( ), ( ) 4, INM803 2,000mg/ kg 14, 2 INM 803 1,600mg/ kg 1,600mg 800 mg/ kg Chinese Hamster Lung (CHL) INM 803CHL. 5. (1) 2 1 Dia b et e s (IF :9.0 19) 1 0 (2) db/ db mouse, ob/ ob mouse ( ).

2003. 6. 1)Kee- W on Kim, H ee- Doo Kim, Jun - Sub Jung, Ran - Sook W oo, H ee- Sun g Kim, H ong - W on Suh, Yung - Hi Kim, Don g - Keun Song : Ch aracterization of antidepressant - like effect s of p - syn ephrine stereoisom er s. Naunyn - Schmiedeberg ' s Archiv es of Pharm acology 364:21-26, 2001. 2)Son g, Don g K., Suh, H ong W., Jun g Jun S., Son, Kun H.,W ie Myung B. an d Kim, Yun g Hi.: Antidepressant - lik e effects of p - synephrin e in m ou se m odels of imm obility tests. Neuroscience Letter s. 214:107-110, 1996. 3) Berthiaume N, Zinker BA. :Metabolic responses in a model of insulin resistance: Comparison between oral glucose and meal tolerance tests. Metabolism. 51(5):595-8, 2002 4) Gueorguiev M, Goth ML, Korbonit s M. Leptin and puberty : a review. Pituitary. Jan - Apr ;4(1-2):79-86, 2001 5) Rosenbaum M, Nicolson M, Hir sch J, Murphy E, Chu F, Leibel RL : Effect s of w eight ch ang e on plasm a leptin concentr ation s an d energy expenditure. J Clin E ndocrinol M etab82 : 3647-3654,1997 6) Saladin R, De Vos P, Guerre- Millo M, Leturque A, Girard J, Staels B, Au w erx J : T ran sient in crease in ob ese gene ex pression after food intake or in sulin administration. N ature377 : 527-529,1995 7)Pelleym ounter MA, Cullen MJ, Baker MB, H echt R, W inter s D, Boone T, Collin s F : Effect s of th e obese gene produ ct on b ody w eight regulation in ob/ ob mice. S cience269 : 540-543,1995 8) Cohen B, Novick D, Rubinstein M : M odulation of insulin activities by leptin. S cience 274:1185-1188, 1996 9) Kam ohara S, Burcelin R, H alaa s JL, Friedman JM, Ch arron MJ : A cute stimulation of glu cose m etabolism in mice by leptin treatment. N ature 389:374-377, 1997 10) Colem an DL Effects of parabiosis of obese w ith diabetes and norm al mice. Diabetologia 9:294298, 1973 11) Pelleym ounter MA, Cullen MJ, Baker MB, Hecht R, W inter s D, Boon e T, Collin s F Effect s of th e obese gene pr odu ct on b ody w eight regulation in ob/ ob mice. S cien ce 269:540543, 1995

7.

0 1- PJ4 - PG4-0 1VN02-0055 ) ( ) ) ( ) 2005 5( 3 ) INM 803 20055.

5 c m 3 c m